Page 6 - Retinal News Today

Revolutionary medical device is first retinal eye-movement monitor for non-invasive, objective clinical assessmentsBOSTON, MA / ACCESSWIRE / May 11, 2023 / C. Light Technologies, Inc., a venture-funded

SOUTH SAN FRANCISCO (dpa-AFX) - Genentech, a member of the Roche Group (RHHBY), said that the U.S. Food and Drug Administration has accepted the company's supplemental Biologics License Application

Acceptance based on two phase III studies that demonstrated early and sustained vision improvement with Vabysmo, meeting primary endpoint of non-inferiority compared to afliberceptApplication was further

Glaukos Corporation , an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced... | May 3, 2023

Glaukos Corporation , an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today... | May 1, 2023

MyJournals.org - Science - Retinal imaging technologies in cerebral malaria: a systematic review (Malaria Journal)

Post-hoc analyses from four phase III studies indicate Vabysmo dried retinal fluid faster with fewer injections in neovascular or 'wet' age-related macular degeneration (nAMD) and diabetic macular edema

Post-hoc analyses from four phase III studies indicate Vabysmo dried retinal fluid faster with fewer injections in neovascular or ‘wet’ age-related macular degeneration and diabetic... | April 25, 2023

‒ Post-hoc analyses from four Phase III studies indicate Vabysmo dried retinal fluid faster with fewer injections in wet age-related macular degeneration and diabetic macular edema ... | April 25, 2023

Post-hoc analyses from four Phase III studies indicate Vabysmo dried retinal fluid faster with fewer injections in wet age-related macular degeneration (AMD) and diabetic macular edema (DME) - More